Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Horizon Completes Enrollment of Japan PIII for Thyroid Eye Disease Drug
Horizon Therapeutics said on November 16 that it has completed the enrollment of its PIII clinical trial in Japan to evaluate teprotumumab, known as Tepezza in the US, for the treatment of active thyroid eye disease (TED). The PIII trial,…
To read the full story
Related Article
- Amgen Files TED Drug Tepezza in Japan
January 17, 2024
- Horizon Japan Eager for Solo Sales of Its 1st Product as Tepezza Trial Likely to Wrap Up Next Year
July 27, 2022
- Horizon Taps Yoshihide Okino as VP and Japan GM
June 8, 2022
- Horizon Launches Japan PIII for Thyroid Eye Disease Drug
February 25, 2022
- Horizon Plants Flag in Japan Soil to Gear Up for Thyroid Eye Disease Trial
December 7, 2021
BUSINESS
- Taiho Moves Araris’ ADC into PI for Lymphoma in US
April 30, 2026
- FDA Accepts Zipalertinib NDA for EGFR Exon 20-Mutant Lung Cancer: Taiho
April 30, 2026
- Sandoz Poaches Regeneron’s Yohei Ishii as Japan Chief
April 30, 2026
- Gilead Files Bictegravir Plus Lenacapavir HIV Pill in Japan
April 30, 2026
- Astellas Tops 2 Trillion Yen in Sales, Gears Up for Post-Xtandi Growth
April 28, 2026
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…